#China #Shanghai #CAR-T therapy #Biotech Innovation #Immunofoco

Immunofoco Achieves Recognition for Pioneering Cancer Treatments

Immunofoco, a clinical-stage biotechnology firm based in Shanghai, has been acknowledged in the prestigious "Forbes Asia 100 to Watch 2025" list. This selection recognizes outstanding small companies and startups in the Asia-Pacific region that showcase innovation and potential for growth. Immunofoco is one of only two companies in the Biotechnology & Healthcare sector from Mainland China to earn this honor.

The Forbes Asia 100 to Watch list is the product of a rigorous selection process focusing on various criteria. Companies are assessed for their positive industry impact, market fit, innovative business models, impressive revenue growth, and fundraising capabilities. This year, 100 companies from 16 different countries are featured, with the Biotechnology & Healthcare sector being the most represented, underlining Asia's emphasis on innovative life sciences solutions.

Innovative Therapies Leading the Charge

Immunofoco has gained attention for its advanced research in cell therapies for solid tumors, notably its EpCAM-targeted CAR-T cell therapy known as IMC001. Recent publications in reputable journals such as Molecular Therapy have highlighted the promising antitumor activity and positive safety profile seen in both preclinical models and clinical trials for advanced gastric cancer patients.

Another milestone includes the adaptation of the Peri Cruiser® technology platform, developed in partnership with experts at Tongji University-affiliated Shanghai East Hospital. This platform addresses critical issues in CAR-T therapies by enhancing the in vivo distribution of CAR-T cells, which minimizes on-target, off-tumor toxicity while maintaining efficacy, thus performing a vital role in solid tumor treatment. The platform even graced the cover of Science Translational Medicine, a testament to its groundbreaking nature.

In terms of product developments, Immunofoco has successfully completed a Phase I registrational trial for IMC002, demonstrating promising safety and efficacy. One notable case involved a patient with advanced gastric cancer and liver metastases who achieved a sustained complete response one year after a single infusion of IMC002. This achievement offers significant hope for patients with advanced solid tumors.

Addressing Challenges with Innovative Solutions

Immunofoco's In Vivo technology platform has also been showcased at the ASGCT 2025 Annual Meeting. By utilizing a distinctive lentiviral vector, this innovative platform enables direct in vivo CAR gene delivery, tackling existing limitations in CAR-T production methodologies, such as the complexity and cost involved in traditional manufacturing processes.

As part of its growth strategy, Immunofoco has successfully raised around $70 million from reputable investors, including Vivo Capital and SDIC Venture Capital Co., Ltd. These funds are crucial for accelerating the clinical development of key product lines such as IMC002 and supporting the company's international expansion initiatives.

Dr. Minmin Sun, the founder and CEO of Immunofoco, emphasizes the importance of this recognition, stating, "This achievement not only belongs to Immunofoco but also underscores the impact of innovation within China's biotech sector on the global stage. We remain dedicated to overcoming solid tumors and delivering transformative cell therapies worldwide."

The Path Ahead

Immunofoco is committed to its vision of curing solid tumors by adopting hematologic malignancy treatment strategies. The company’s innovative approaches, including the Peri Cruiser® and enhanced CAR-T strategies, aim to address safety concerns while maximizing treatment effectiveness in solid tumors. As it continues to advance its diverse product pipeline, including IMC002 and IMC001, Immunofoco embodies the spirit of innovation and dedication necessary to redefine cancer treatment.

For additional information about Immunofoco, you can visit their official website.